This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.
Testing the association between subtypes identified by 12 different clustering approaches and 5 clinical features across 478 patients, 22 significant findings detected with P value < 0.05 and Q value < 0.25.
-
CNMF clustering analysis on array-based mRNA expression data identified 4 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.
-
6 subtypes identified in current cancer cohort by 'Copy Number Ratio CNMF subtypes'. These subtypes correlate to 'Time to Death', 'AGE', and 'HISTOLOGICAL.TYPE'.
-
3 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.
-
CNMF clustering analysis on RPPA data identified 6 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on RPPA data identified 2 subtypes that correlate to 'HISTOLOGICAL.TYPE' and 'COMPLETENESS.OF.RESECTION'.
-
CNMF clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
5 subtypes identified in current cancer cohort by 'MIRSEQ CNMF'. These subtypes correlate to 'Time to Death', 'AGE', 'HISTOLOGICAL.TYPE', and 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
3 subtypes identified in current cancer cohort by 'MIRSEQ CHIERARCHICAL'. These subtypes correlate to 'Time to Death', 'AGE', and 'HISTOLOGICAL.TYPE'.
-
3 subtypes identified in current cancer cohort by 'MIRseq Mature CNMF subtypes'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.
-
4 subtypes identified in current cancer cohort by 'MIRseq Mature cHierClus subtypes'. These subtypes correlate to 'Time to Death' and 'HISTOLOGICAL.TYPE'.
Clinical Features |
Time to Death |
AGE |
HISTOLOGICAL TYPE |
RADIATIONS RADIATION REGIMENINDICATION |
COMPLETENESS OF RESECTION |
Statistical Tests | logrank test | ANOVA | Chi-square test | Fisher's exact test | Chi-square test |
mRNA CNMF subtypes |
0.858 (1.00) |
0.0116 (0.429) |
0.00151 (0.065) |
0.0371 (1.00) |
0.855 (1.00) |
mRNA cHierClus subtypes |
0.727 (1.00) |
0.00301 (0.12) |
9.4e-05 (0.00489) |
0.0234 (0.82) |
0.677 (1.00) |
Copy Number Ratio CNMF subtypes |
0.00156 (0.0654) |
1.37e-09 (7.42e-08) |
7.4e-45 (4.44e-43) |
0.0213 (0.768) |
0.398 (1.00) |
METHLYATION CNMF |
0.00762 (0.29) |
0.0332 (1.00) |
1.26e-23 (7.17e-22) |
0.121 (1.00) |
0.0713 (1.00) |
RPPA CNMF subtypes |
0.0702 (1.00) |
0.203 (1.00) |
0.00103 (0.0464) |
0.461 (1.00) |
0.102 (1.00) |
RPPA cHierClus subtypes |
0.089 (1.00) |
0.236 (1.00) |
0.000814 (0.0383) |
0.46 (1.00) |
0.00347 (0.135) |
RNAseq CNMF subtypes |
0.61 (1.00) |
0.0342 (1.00) |
0.000159 (0.00797) |
0.104 (1.00) |
0.58 (1.00) |
RNAseq cHierClus subtypes |
0.914 (1.00) |
0.0752 (1.00) |
0.000338 (0.0162) |
0.23 (1.00) |
0.265 (1.00) |
MIRSEQ CNMF |
0.00112 (0.0492) |
7.57e-08 (4.01e-06) |
7.25e-27 (4.28e-25) |
0.000231 (0.0113) |
0.0804 (1.00) |
MIRSEQ CHIERARCHICAL |
0.000953 (0.0438) |
0.000145 (0.0074) |
3.89e-24 (2.26e-22) |
0.309 (1.00) |
0.633 (1.00) |
MIRseq Mature CNMF subtypes |
0.0635 (1.00) |
0.0687 (1.00) |
1.79e-11 (9.85e-10) |
0.547 (1.00) |
0.0452 (1.00) |
MIRseq Mature cHierClus subtypes |
0.00264 (0.108) |
0.0589 (1.00) |
3.8e-19 (2.13e-17) |
0.436 (1.00) |
0.256 (1.00) |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 14 | 18 | 12 | 10 |
P value = 0.858 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 54 | 9 | 6.0 - 149.5 (37.4) |
subtype1 | 14 | 2 | 13.6 - 149.5 (41.7) |
subtype2 | 18 | 4 | 6.0 - 125.4 (46.2) |
subtype3 | 12 | 1 | 12.7 - 105.4 (31.1) |
subtype4 | 10 | 2 | 7.9 - 82.5 (28.3) |
P value = 0.0116 (ANOVA), Q value = 0.43
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 54 | 62.9 (11.8) |
subtype1 | 14 | 65.6 (11.7) |
subtype2 | 18 | 68.2 (9.3) |
subtype3 | 12 | 58.7 (11.9) |
subtype4 | 10 | 54.9 (11.5) |
P value = 0.00151 (Chi-square test), Q value = 0.065
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 41 | 1 | 12 |
subtype1 | 12 | 0 | 2 |
subtype2 | 8 | 0 | 10 |
subtype3 | 11 | 1 | 0 |
subtype4 | 10 | 0 | 0 |
P value = 0.0371 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 25 | 29 |
subtype1 | 8 | 6 |
subtype2 | 12 | 6 |
subtype3 | 3 | 9 |
subtype4 | 2 | 8 |
P value = 0.855 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 39 | 6 | 2 | 1 |
subtype1 | 8 | 2 | 1 | 0 |
subtype2 | 14 | 1 | 1 | 1 |
subtype3 | 9 | 2 | 0 | 0 |
subtype4 | 8 | 1 | 0 | 0 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 19 | 19 | 16 |
P value = 0.727 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 54 | 9 | 6.0 - 149.5 (37.4) |
subtype1 | 19 | 3 | 13.6 - 149.5 (46.5) |
subtype2 | 19 | 2 | 7.9 - 105.4 (28.3) |
subtype3 | 16 | 4 | 6.0 - 125.4 (46.2) |
P value = 0.00301 (ANOVA), Q value = 0.12
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 54 | 62.9 (11.8) |
subtype1 | 19 | 63.9 (10.5) |
subtype2 | 19 | 56.4 (12.5) |
subtype3 | 16 | 69.5 (8.7) |
P value = 9.4e-05 (Chi-square test), Q value = 0.0049
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 41 | 1 | 12 |
subtype1 | 16 | 1 | 2 |
subtype2 | 19 | 0 | 0 |
subtype3 | 6 | 0 | 10 |
P value = 0.0234 (Fisher's exact test), Q value = 0.82
nPatients | NO | YES |
---|---|---|
ALL | 25 | 29 |
subtype1 | 11 | 8 |
subtype2 | 4 | 15 |
subtype3 | 10 | 6 |
P value = 0.677 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 39 | 6 | 2 | 1 |
subtype1 | 13 | 2 | 1 | 0 |
subtype2 | 13 | 3 | 0 | 0 |
subtype3 | 13 | 1 | 1 | 1 |
Cluster Labels | 1 | 2 | 3 | 4 | 5 | 6 |
---|---|---|---|---|---|---|
Number of samples | 280 | 8 | 138 | 12 | 20 | 12 |
P value = 0.00156 (logrank test), Q value = 0.065
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 467 | 56 | 0.0 - 191.8 (20.9) |
subtype1 | 278 | 22 | 0.1 - 191.8 (24.3) |
subtype2 | 8 | 3 | 0.5 - 149.5 (14.7) |
subtype3 | 137 | 26 | 0.0 - 125.4 (15.1) |
subtype4 | 12 | 1 | 8.0 - 68.3 (22.1) |
subtype5 | 20 | 2 | 0.2 - 72.7 (16.5) |
subtype6 | 12 | 2 | 8.5 - 73.2 (30.4) |
P value = 1.37e-09 (ANOVA), Q value = 7.4e-08
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 469 | 63.8 (11.3) |
subtype1 | 279 | 61.4 (11.2) |
subtype2 | 8 | 64.1 (11.8) |
subtype3 | 138 | 69.3 (8.9) |
subtype4 | 12 | 62.7 (11.0) |
subtype5 | 20 | 60.6 (14.1) |
subtype6 | 12 | 61.2 (11.8) |
P value = 7.4e-45 (Chi-square test), Q value = 4.4e-43
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 359 | 18 | 93 |
subtype1 | 267 | 8 | 5 |
subtype2 | 5 | 0 | 3 |
subtype3 | 44 | 9 | 85 |
subtype4 | 11 | 1 | 0 |
subtype5 | 20 | 0 | 0 |
subtype6 | 12 | 0 | 0 |
P value = 0.0213 (Chi-square test), Q value = 0.77
nPatients | NO | YES |
---|---|---|
ALL | 135 | 335 |
subtype1 | 95 | 185 |
subtype2 | 1 | 7 |
subtype3 | 29 | 109 |
subtype4 | 5 | 7 |
subtype5 | 2 | 18 |
subtype6 | 3 | 9 |
P value = 0.398 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 324 | 24 | 16 | 26 |
subtype1 | 199 | 14 | 4 | 15 |
subtype2 | 5 | 0 | 0 | 1 |
subtype3 | 90 | 8 | 10 | 8 |
subtype4 | 9 | 1 | 1 | 0 |
subtype5 | 12 | 1 | 1 | 2 |
subtype6 | 9 | 0 | 0 | 0 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 131 | 81 | 150 |
P value = 0.00762 (logrank test), Q value = 0.29
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 359 | 41 | 0.0 - 191.8 (16.8) |
subtype1 | 129 | 23 | 0.0 - 191.8 (13.8) |
subtype2 | 81 | 5 | 0.1 - 102.0 (22.5) |
subtype3 | 149 | 13 | 0.1 - 185.8 (17.0) |
P value = 0.0332 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 361 | 63.9 (11.3) |
subtype1 | 130 | 65.8 (10.6) |
subtype2 | 81 | 63.9 (12.8) |
subtype3 | 150 | 62.3 (10.9) |
P value = 1.26e-23 (Chi-square test), Q value = 7.2e-22
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 267 | 17 | 78 |
subtype1 | 56 | 12 | 63 |
subtype2 | 64 | 2 | 15 |
subtype3 | 147 | 3 | 0 |
P value = 0.121 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 84 | 278 |
subtype1 | 34 | 97 |
subtype2 | 12 | 69 |
subtype3 | 38 | 112 |
P value = 0.0713 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 240 | 18 | 12 | 25 |
subtype1 | 84 | 8 | 7 | 9 |
subtype2 | 51 | 4 | 4 | 10 |
subtype3 | 105 | 6 | 1 | 6 |
Cluster Labels | 1 | 2 | 3 | 4 | 5 | 6 |
---|---|---|---|---|---|---|
Number of samples | 42 | 39 | 40 | 12 | 41 | 26 |
P value = 0.0702 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 200 | 20 | 0.6 - 185.8 (28.9) |
subtype1 | 42 | 4 | 0.6 - 106.9 (29.5) |
subtype2 | 39 | 6 | 6.0 - 149.5 (28.1) |
subtype3 | 40 | 1 | 1.8 - 185.8 (29.9) |
subtype4 | 12 | 4 | 1.4 - 87.3 (35.2) |
subtype5 | 41 | 2 | 0.7 - 113.3 (24.6) |
subtype6 | 26 | 3 | 0.7 - 78.2 (29.6) |
P value = 0.203 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 200 | 62.7 (11.1) |
subtype1 | 42 | 62.3 (12.7) |
subtype2 | 39 | 64.2 (9.6) |
subtype3 | 40 | 62.2 (11.2) |
subtype4 | 12 | 69.8 (8.5) |
subtype5 | 41 | 60.7 (9.4) |
subtype6 | 26 | 62.0 (12.8) |
P value = 0.00103 (Chi-square test), Q value = 0.046
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 174 | 3 | 23 |
subtype1 | 35 | 1 | 6 |
subtype2 | 28 | 0 | 11 |
subtype3 | 39 | 1 | 0 |
subtype4 | 12 | 0 | 0 |
subtype5 | 41 | 0 | 0 |
subtype6 | 19 | 1 | 6 |
P value = 0.461 (Chi-square test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 80 | 120 |
subtype1 | 20 | 22 |
subtype2 | 19 | 20 |
subtype3 | 13 | 27 |
subtype4 | 4 | 8 |
subtype5 | 13 | 28 |
subtype6 | 11 | 15 |
P value = 0.102 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 141 | 9 | 5 | 16 |
subtype1 | 24 | 3 | 3 | 6 |
subtype2 | 29 | 1 | 1 | 2 |
subtype3 | 26 | 0 | 0 | 5 |
subtype4 | 10 | 1 | 1 | 0 |
subtype5 | 30 | 4 | 0 | 1 |
subtype6 | 22 | 0 | 0 | 2 |
Cluster Labels | 1 | 2 |
---|---|---|
Number of samples | 124 | 76 |
P value = 0.089 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 200 | 20 | 0.6 - 185.8 (28.9) |
subtype1 | 124 | 9 | 0.7 - 185.8 (29.7) |
subtype2 | 76 | 11 | 0.6 - 149.5 (23.9) |
P value = 0.236 (t-test), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 200 | 62.7 (11.1) |
subtype1 | 124 | 62.0 (10.9) |
subtype2 | 76 | 63.9 (11.3) |
P value = 0.000814 (Chi-square test), Q value = 0.038
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 174 | 3 | 23 |
subtype1 | 116 | 2 | 6 |
subtype2 | 58 | 1 | 17 |
P value = 0.46 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 80 | 120 |
subtype1 | 47 | 77 |
subtype2 | 33 | 43 |
P value = 0.00347 (Chi-square test), Q value = 0.14
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 141 | 9 | 5 | 16 |
subtype1 | 94 | 6 | 0 | 6 |
subtype2 | 47 | 3 | 5 | 10 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 39 | 25 | 21 |
P value = 0.61 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 83 | 12 | 0.0 - 102.0 (5.3) |
subtype1 | 38 | 6 | 0.0 - 102.0 (4.2) |
subtype2 | 24 | 3 | 0.1 - 91.0 (11.9) |
subtype3 | 21 | 3 | 0.1 - 43.3 (4.7) |
P value = 0.0342 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 84 | 65.7 (11.7) |
subtype1 | 39 | 67.0 (12.2) |
subtype2 | 24 | 60.6 (11.5) |
subtype3 | 21 | 69.0 (9.3) |
P value = 0.000159 (Chi-square test), Q value = 0.008
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 46 | 5 | 34 |
subtype1 | 12 | 1 | 26 |
subtype2 | 18 | 3 | 4 |
subtype3 | 16 | 1 | 4 |
P value = 0.104 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 6 | 79 |
subtype1 | 1 | 38 |
subtype2 | 4 | 21 |
subtype3 | 1 | 20 |
P value = 0.58 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 52 | 2 | 4 | 4 |
subtype1 | 22 | 1 | 2 | 3 |
subtype2 | 15 | 1 | 2 | 0 |
subtype3 | 15 | 0 | 0 | 1 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 35 | 27 | 23 |
P value = 0.914 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 83 | 12 | 0.0 - 102.0 (5.3) |
subtype1 | 34 | 6 | 0.0 - 102.0 (4.2) |
subtype2 | 26 | 4 | 0.1 - 91.0 (9.8) |
subtype3 | 23 | 2 | 0.1 - 62.1 (5.3) |
P value = 0.0752 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 84 | 65.7 (11.7) |
subtype1 | 35 | 68.1 (12.6) |
subtype2 | 26 | 61.4 (8.9) |
subtype3 | 23 | 66.7 (12.2) |
P value = 0.000338 (Chi-square test), Q value = 0.016
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 46 | 5 | 34 |
subtype1 | 10 | 2 | 23 |
subtype2 | 16 | 2 | 9 |
subtype3 | 20 | 1 | 2 |
P value = 0.23 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 6 | 79 |
subtype1 | 1 | 34 |
subtype2 | 4 | 23 |
subtype3 | 1 | 22 |
P value = 0.265 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 52 | 2 | 4 | 4 |
subtype1 | 19 | 0 | 1 | 2 |
subtype2 | 16 | 2 | 3 | 1 |
subtype3 | 17 | 0 | 0 | 1 |
Cluster Labels | 1 | 2 | 3 | 4 | 5 |
---|---|---|---|---|---|
Number of samples | 131 | 128 | 45 | 53 | 112 |
P value = 0.00112 (logrank test), Q value = 0.049
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 466 | 53 | 0.0 - 191.8 (20.9) |
subtype1 | 129 | 22 | 0.0 - 125.4 (15.0) |
subtype2 | 128 | 5 | 0.1 - 113.3 (24.3) |
subtype3 | 44 | 4 | 0.9 - 88.3 (23.5) |
subtype4 | 53 | 9 | 0.2 - 96.5 (17.4) |
subtype5 | 112 | 13 | 1.0 - 191.8 (31.1) |
P value = 7.57e-08 (ANOVA), Q value = 4e-06
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 468 | 63.7 (11.3) |
subtype1 | 131 | 68.1 (9.9) |
subtype2 | 128 | 63.4 (10.8) |
subtype3 | 44 | 64.6 (11.5) |
subtype4 | 53 | 59.3 (12.3) |
subtype5 | 112 | 60.4 (11.2) |
P value = 7.25e-27 (Chi-square test), Q value = 4.3e-25
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 362 | 18 | 89 |
subtype1 | 56 | 9 | 66 |
subtype2 | 124 | 2 | 2 |
subtype3 | 32 | 1 | 12 |
subtype4 | 50 | 2 | 1 |
subtype5 | 100 | 4 | 8 |
P value = 0.000231 (Chi-square test), Q value = 0.011
nPatients | NO | YES |
---|---|---|
ALL | 131 | 338 |
subtype1 | 27 | 104 |
subtype2 | 30 | 98 |
subtype3 | 13 | 32 |
subtype4 | 11 | 42 |
subtype5 | 50 | 62 |
P value = 0.0804 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 322 | 24 | 15 | 26 |
subtype1 | 76 | 10 | 9 | 9 |
subtype2 | 94 | 3 | 1 | 8 |
subtype3 | 36 | 3 | 0 | 2 |
subtype4 | 37 | 2 | 1 | 4 |
subtype5 | 79 | 6 | 4 | 3 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 24 | 220 | 225 |
P value = 0.000953 (logrank test), Q value = 0.044
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 466 | 53 | 0.0 - 191.8 (20.9) |
subtype1 | 24 | 2 | 1.4 - 73.2 (21.7) |
subtype2 | 220 | 14 | 0.1 - 185.8 (24.3) |
subtype3 | 222 | 37 | 0.0 - 191.8 (17.6) |
P value = 0.000145 (ANOVA), Q value = 0.0074
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 468 | 63.7 (11.3) |
subtype1 | 24 | 60.8 (10.8) |
subtype2 | 220 | 61.7 (11.5) |
subtype3 | 224 | 65.9 (10.8) |
P value = 3.89e-24 (Chi-square test), Q value = 2.3e-22
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 362 | 18 | 89 |
subtype1 | 24 | 0 | 0 |
subtype2 | 213 | 3 | 4 |
subtype3 | 125 | 15 | 85 |
P value = 0.309 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 131 | 338 |
subtype1 | 10 | 14 |
subtype2 | 59 | 161 |
subtype3 | 62 | 163 |
P value = 0.633 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 322 | 24 | 15 | 26 |
subtype1 | 16 | 2 | 0 | 1 |
subtype2 | 150 | 10 | 5 | 15 |
subtype3 | 156 | 12 | 10 | 10 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 148 | 112 | 82 |
P value = 0.0635 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 339 | 42 | 0.0 - 191.8 (16.6) |
subtype1 | 145 | 22 | 0.0 - 191.8 (14.0) |
subtype2 | 112 | 7 | 0.1 - 113.3 (19.4) |
subtype3 | 82 | 13 | 0.1 - 92.0 (21.8) |
P value = 0.0687 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 341 | 64.3 (11.3) |
subtype1 | 147 | 65.9 (11.2) |
subtype2 | 112 | 63.5 (10.1) |
subtype3 | 82 | 62.5 (12.7) |
P value = 1.79e-11 (Chi-square test), Q value = 9.9e-10
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 249 | 16 | 77 |
subtype1 | 85 | 8 | 55 |
subtype2 | 109 | 1 | 2 |
subtype3 | 55 | 7 | 20 |
P value = 0.547 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 82 | 260 |
subtype1 | 32 | 116 |
subtype2 | 27 | 85 |
subtype3 | 23 | 59 |
P value = 0.0452 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 231 | 17 | 12 | 20 |
subtype1 | 95 | 9 | 10 | 6 |
subtype2 | 73 | 4 | 2 | 10 |
subtype3 | 63 | 4 | 0 | 4 |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 89 | 132 | 96 | 25 |
P value = 0.00264 (logrank test), Q value = 0.11
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 339 | 42 | 0.0 - 191.8 (16.6) |
subtype1 | 88 | 11 | 0.1 - 92.0 (16.8) |
subtype2 | 132 | 7 | 0.1 - 88.3 (18.6) |
subtype3 | 94 | 17 | 0.0 - 191.8 (14.6) |
subtype4 | 25 | 7 | 0.2 - 60.5 (12.3) |
P value = 0.0589 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 341 | 64.3 (11.3) |
subtype1 | 88 | 64.1 (11.4) |
subtype2 | 132 | 62.7 (11.3) |
subtype3 | 96 | 66.8 (10.1) |
subtype4 | 25 | 64.2 (13.8) |
P value = 3.8e-19 (Chi-square test), Q value = 2.1e-17
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 249 | 16 | 77 |
subtype1 | 58 | 5 | 26 |
subtype2 | 128 | 2 | 2 |
subtype3 | 39 | 9 | 48 |
subtype4 | 24 | 0 | 1 |
P value = 0.436 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 82 | 260 |
subtype1 | 25 | 64 |
subtype2 | 34 | 98 |
subtype3 | 19 | 77 |
subtype4 | 4 | 21 |
P value = 0.256 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 231 | 17 | 12 | 20 |
subtype1 | 66 | 4 | 2 | 4 |
subtype2 | 91 | 4 | 2 | 10 |
subtype3 | 58 | 7 | 7 | 4 |
subtype4 | 16 | 2 | 1 | 2 |
-
Cluster data file = UCEC-TP.mergedcluster.txt
-
Clinical data file = UCEC-TP.clin.merged.picked.txt
-
Number of patients = 478
-
Number of clustering approaches = 12
-
Number of selected clinical features = 5
-
Exclude small clusters that include fewer than K patients, K = 3
consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)
Resampling-based clustering method (Monti et al. 2003)
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R
For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R
For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R
For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between two tumor subtypes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.